US Patent

US8933097 — Fexofenadine suspension formulation

Formulation · Assigned to Sanofi Aventis US LLC · Expires 2030-08-02 · 4y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects an aqueous pharmaceutical suspension formulation of fexofenadine zwitterionic dihydrate Form I.

USPTO Abstract

The present invention is directed to an aqueous pharmaceutical suspension of fexofenadine zwitterionic dihydrate Form I.

Drugs covered by this patent

fexofenadine-hydrochloride (FEXOFENADINE HYDROCHLORIDE)

Patent Metadata

Patent number: US8933097
Jurisdiction: US
Classification: Formulation
Expires: 2030-08-02
Drug substance claim: No
Drug product claim: Yes
Assignee: Sanofi Aventis US LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.